BMIQ4
MCID: BDY010
MIFTS: 47

Body Mass Index Quantitative Trait Locus 4 (BMIQ4)

Categories: Bone diseases, Genetic diseases, Metabolic diseases

Aliases & Classifications for Body Mass Index Quantitative Trait Locus 4

MalaCards integrated aliases for Body Mass Index Quantitative Trait Locus 4:

Name: Body Mass Index Quantitative Trait Locus 4 56 29 6 39
Obesity, Susceptibility to, Bmiq4 56 13
Obesity 56 71
Obesity, Susceptibility to 56
Obesity Bmiq4 56
Bmiq4 56

Classifications:



External Ids:

OMIM 56 607447
UMLS 71 C0028754

Summaries for Body Mass Index Quantitative Trait Locus 4

MalaCards based summary : Body Mass Index Quantitative Trait Locus 4, also known as obesity, susceptibility to, bmiq4, is related to body mass index quantitative trait locus 11 and obesity, early-onset, with adrenal insufficiency and red hair, and has symptoms including symptoms, high weight and obesity, metabolically benign. An important gene associated with Body Mass Index Quantitative Trait Locus 4 is UCP2 (Uncoupling Protein 2). The drugs Oseltamivir and Citalopram have been mentioned in the context of this disorder. Affiliated tissues include liver, heart and breast.

More information from OMIM: 607447

Related Diseases for Body Mass Index Quantitative Trait Locus 4

Diseases in the Body Mass Index Quantitative Trait Locus 11 family:

Body Mass Index Quantitative Trait Locus 9 Body Mass Index Quantitative Trait Locus 8
Body Mass Index Quantitative Trait Locus 1 Body Mass Index Quantitative Trait Locus 2
Body Mass Index Quantitative Trait Locus 3 Body Mass Index Quantitative Trait Locus 4
Body Mass Index Quantitative Trait Locus 10 Body Mass Index Quantitative Trait Locus 7
Body Mass Index Quantitative Trait Locus 5 Body Mass Index Quantitative Trait Locus 6
Body Mass Index Quantitative Trait Locus 12 Body Mass Index Quantitative Trait Locus 13
Body Mass Index Quantitative Trait Locus 14 Body Mass Index Quantitative Trait Locus 15
Body Mass Index Quantitative Trait Locus 18 Body Mass Index Quantitative Trait Locus 19
Body Mass Index Quantitative Trait Locus 20

Diseases related to Body Mass Index Quantitative Trait Locus 4 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 2043)
# Related Disease Score Top Affiliating Genes
1 body mass index quantitative trait locus 11 12.7
2 obesity, early-onset, with adrenal insufficiency and red hair 12.7
3 morbid obesity and spermatogenic failure 12.7
4 leptin deficiency or dysfunction 12.6
5 genetic obesity 12.6
6 obesity-hypoventilation syndrome 12.6
7 mental retardation, truncal obesity, retinal dystrophy, and micropenis syndrome 12.5
8 obesity, hyperphagia, and developmental delay 12.5
9 abdominal obesity-metabolic syndrome 1 12.5
10 spastic paraplegia, intellectual disability, nystagmus, and obesity 12.5
11 retinal dystrophy and obesity 12.5
12 abdominal obesity-metabolic syndrome 3 12.5
13 wilms tumor, aniridia, genitourinary anomalies, mental retardation, and obesity syndrome 12.5
14 hypothalamic obesity 12.5
15 hydrocephalus obesity hypogonadism 12.4
16 x-linked intellectual disability - short stature - obesity 12.4
17 body mass index quantitative trait locus 19 12.4
18 leptin receptor deficiency 12.3
19 body mass index quantitative trait locus 20 12.3
20 abdominal obesity-metabolic syndrome quantitative trait locus 2 12.3
21 aniridia - ptosis - intellectual disability - familial obesity 12.3
22 obesity due to melanocortin 4 receptor deficiency 12.3
23 abdominal obesity-metabolic syndrome 4 12.3
24 rapid-onset childhood obesity-hypothalamic dysfunction-hypoventilation-autonomic dysregulation syndrome 12.2
25 coloboma-obesity-hypogenitalism-mental retardation syndrome 12.2
26 short stature-obesity syndrome 12.2
27 mental retardation, obesity, mandibular prognathism, and eye and skin anomalies 12.2
28 prolactin deficiency with obesity and enlarged testes 12.2
29 obesity due to congenital leptin resistance 12.2
30 severe early-onset obesity-insulin resistance syndrome due to sh2b1 deficiency 12.2
31 obesity due to sim1 deficiency 12.2
32 wilson-turner x-linked mental retardation syndrome 12.2
33 syndromic obesity 12.2
34 body mass index quantitative trait locus 9 12.2
35 body mass index quantitative trait locus 12 12.2
36 cohen syndrome 12.2
37 body mass index quantitative trait locus 14 12.2
38 body mass index quantitative trait locus 8 12.2
39 body mass index quantitative trait locus 7 12.2
40 body mass index quantitative trait locus 18 12.2
41 midface hypoplasia, obesity, developmental delay, and neonatal hypotonia 12.2
42 mehmo syndrome 12.1
43 body mass index quantitative trait locus 10 12.1
44 proprotein convertase 1/3 deficiency 12.1
45 genetic non-syndromic obesity 12.1
46 momo syndrome 12.1
47 chung-jansen syndrome 12.1
48 chops syndrome 12.1
49 genetic overgrowth/obesity syndrome 12.0
50 overgrowth/obesity syndrome 12.0

Graphical network of the top 20 diseases related to Body Mass Index Quantitative Trait Locus 4:



Diseases related to Body Mass Index Quantitative Trait Locus 4

Symptoms & Phenotypes for Body Mass Index Quantitative Trait Locus 4

Clinical features from OMIM:

607447

UMLS symptoms related to Body Mass Index Quantitative Trait Locus 4:


symptoms, high weight, obesity, metabolically benign, monogenic obesity

Drugs & Therapeutics for Body Mass Index Quantitative Trait Locus 4

Drugs for Body Mass Index Quantitative Trait Locus 4 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1166)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Oseltamivir Approved Phase 4 204255-11-8, 196618-13-0 65028
2
Citalopram Approved Phase 4 59729-33-8 2771
3
Enalapril Approved, Vet_approved Phase 4 75847-73-3 5362032 40466924
4
Enalaprilat Approved Phase 4 76420-72-9 6917719
5
Erythromycin Approved, Investigational, Vet_approved Phase 4 114-07-8 12560 441411
6
Vancomycin Approved Phase 4 1404-90-6 441141 14969
7
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
8
Lixisenatide Approved Phase 4 320367-13-3
9
Ceftaroline fosamil Approved, Investigational Phase 4 229016-73-3
10
Metyrapone Approved, Investigational Phase 4 54-36-4 4174
11
Ticagrelor Approved Phase 4 274693-27-5 9871419
12
Dexlansoprazole Approved, Investigational Phase 4 138530-94-6, 103577-45-3 9578005
13
Lansoprazole Approved, Investigational Phase 4 103577-45-3 3883
14
Tolnaftate Approved, Investigational, Vet_approved Phase 4 2398-96-1 5510
15
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
16
Dapsone Approved, Investigational Phase 4 80-08-0 2955
17
Caspofungin Approved Phase 4 179463-17-3, 162808-62-0 468682 2826718
18
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
19
Iron Approved, Experimental Phase 4 7439-89-6, 15438-31-0 23925 27284
20
Meropenem Approved, Investigational Phase 4 119478-56-7, 96036-03-2 441130 64778
21
Ertapenem Approved, Investigational Phase 4 153832-46-3 150610
22
Vildagliptin Approved, Investigational Phase 4 274901-16-5 6918537
23
Adenosine Approved, Investigational Phase 4 58-61-7 60961
24
Metronidazole Approved Phase 4 443-48-1 4173
25
Cisplatin Approved Phase 4 15663-27-1 84093 441203 2767
26
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
27
Tocopherol Approved, Investigational Phase 4 1406-66-2, 54-28-4 14986
28
Selenium Approved, Investigational, Vet_approved Phase 4 7782-49-2
29
Zonisamide Approved, Investigational Phase 4 68291-97-4 5734
30
Losartan Approved Phase 4 114798-26-4 3961
31
Enoxaparin Approved Phase 4 9005-49-6 772
32
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
33
Pitavastatin Approved Phase 4 147526-32-7, 147511-69-1 6366718 5282452
34
Olmesartan Approved, Investigational Phase 4 144689-63-4, 144689-24-7 158781 130881
35
Ibuprofen Approved Phase 4 15687-27-1 3672
36
Fluoxetine Approved, Vet_approved Phase 4 54910-89-3 3386
37
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
38
Sodium citrate Approved, Investigational Phase 4 68-04-2
39
Infliximab Approved Phase 4 170277-31-3
40
Tadalafil Approved, Investigational Phase 4 171596-29-5 110635
41
Nadroparin Approved, Investigational Phase 4
42
Pentoxifylline Approved, Investigational Phase 4 6493-05-6 4740
43
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
44
Racepinephrine Approved Phase 4 329-65-7 838
45
Tigecycline Approved Phase 4 220620-09-7 5282044
46
Memantine Approved, Investigational Phase 4 19982-08-2 4054
47
Lactulose Approved Phase 4 4618-18-2 11333
48
Cefuroxime Approved Phase 4 55268-75-2 5479529 5361202
49
Ethambutol Approved Phase 4 74-55-5 3279 14052
50
Ziprasidone Approved Phase 4 146939-27-7 60854

Interventional clinical trials:

(show top 50) (show all 10000)
# Name Status NCT ID Phase Drugs
1 Double Blinded Randomised Trial Comparing Metformin Versus Placebo in NASH Patients Receiving Bariatric Surgery for Obesity Unknown status NCT00134303 Phase 4 Metformin
2 Effect of Bile Acids and Bile Acid Sequstrants on GLP-1 Secretion After Roux-en-Y Gastric Bypass Unknown status NCT02952963 Phase 4 Chenodeoxycholic Acid;Colesevelam
3 The Effect of Obesity in Dexmedetomidine Metabolic Clearance Unknown status NCT02557867 Phase 4 Dexmedetomidine
4 The Effect of Moxonidine and Regression of Early Target Organ Damage in Young Subjects With Abdominal Obesity and Hypertension: a Randomised, Double Blind, Active Comparator Clinical Trial Unknown status NCT01360710 Phase 4 Moxonidine;Irbesartan
5 Effect of Acarbose and Vildagliptin on Visceral Fat Distribution in Overweight and Obesity Patients With Newly Diagnosed Type 2 Diabetes Mellitus: A Randomized Control Study Unknown status NCT02999841 Phase 4 Acarbose;Vildagliptin
6 Assessment of the Effect of Moxonidine and Diet on Cardiac, Renal and Endothelial Function in Young Subjects With Abdominal Obesity Unknown status NCT01180231 Phase 4 Moxonidine (Physiotens)
7 Obesity Cohort : Medical Follow-up of Severe or Morbid Obese Patients Undergoing Bariatric Surgery Unknown status NCT02310178 Phase 4
8 The Effect of Vitamin A Supplementation on CD4+ T-cell Secretion in Obese Individuals Unknown status NCT01405352 Phase 4
9 Effects of Chenodeoxycholic Acid and Colesevelam on GLP-1 Secretion, During a Meal, After Roux-en-Y Gastric Bypass Unknown status NCT02876484 Phase 4 Colesevelam;Chenodeoxycholic Acid
10 A Study of the Pharmacokinetics of Dexmedetomidine in Morbid Obesity. Unknown status NCT01864187 Phase 4 Dexmedetomidine
11 Effect of Saxagliptin on Body Fat , Glucose and Beta Cell Function in Patients With Newly Diagnosed Pre-Diabetes Mellitus and Obesity Unknown status NCT01960205 Phase 4 Saxagliptin;saxagliptin;metformin
12 Evaluation of the Effects of Laying Early (Between 12 and 16) a Gastric Band on the Prevention of Morbid Obesity in Late Adolescence. Randomized Checked Against Standard Management of Obesity in This Population. Unknown status NCT01700738 Phase 4
13 Prevention and Control of Obesity in Primary School Children in Tehran Unknown status NCT02082080 Phase 4
14 Levonorgestrel-releasing Intrauterine Device Effects on Hemostatic and Arterial Function of Obese Women Unknown status NCT01320917 Phase 4
15 Healthy Opportunities for Physical Activity and Nutrition (HOP'N) After-School Project Unknown status NCT01015599 Phase 4
16 Impact of the Preservation of the Gastric Antrum in the Technique of Sleeve Gastrectomy for the Treatment of the Morbid Obesity: a Prospective,Controlled, Randomized, Multicentrique Study. Unknown status NCT01550601 Phase 4
17 Laparoscopic Roux-en-Y Gastric Bypass vs. Laparoscopic BPD-Duodenal Switch for Superobesity (BMI > 50 kg/m2)- A Randomized Clinical Trial Unknown status NCT00327912 Phase 4
18 Evaluation of Family Intervention Program for the Treatment of Overweight or Obese Children (Nereu Program): Randomized Clinical Trial Unknown status NCT01878994 Phase 4
19 Children's Healthy Living Program for Remote Underserved Minority Populations in the Pacific Region Unknown status NCT01881373 Phase 4
20 Prospective, Pharmacokinetic Study for Determination of the Relationship Between Lean Body Weight and Anti-Xa Activity 4 Hours After Subcutaneous Injection of 5700 IU Nadroparin in Morbidly Obese Patients After Bariatric Surgery. Unknown status NCT02295150 Phase 4 Nadroparin
21 Randomisation to Endoluminal Intestinal Liner Alone Versus With Incretin Analogue in SustainEd Diabesity (REVISE-Diabesity) Unknown status NCT02055014 Phase 4 Liraglutide
22 Laparoscopic Bariatric Surgery: Impact of the Level of Neuromuscular Blockade on Surgical Conditions - Comparison Between Moderate and Deep Neuromuscular Blockade Unknown status NCT02118844 Phase 4 rocuronium
23 Beijing Chao-yang Hospital, Capital Medical University Unknown status NCT02583438 Phase 4 Saxagliptin (Bristol-Myers Squibb Company)
24 Correlation of Postoperative VAS Values and Body Mass Index in Patients Undergoing Abdominal Surgery: A Clinical Trial Unknown status NCT02017314 Phase 4 Morphine
25 Laparoscopic Non Banded Vertical (Magenstrasse and Mill) Gastroplasty In Bariatric Surgery. Morbidity and Results on Weight Loss and Associated Co-morbidities Unknown status NCT02050477 Phase 4
26 Double-blind Randomized Trial Using Oral Metformin Versus Placebo in the Treatment of Acanthosis Nigricans in Children With Obesity Unknown status NCT02438020 Phase 4 Metformin
27 The Therapeutic Effect of Catgut Embedding in Obesity-A Randomized, Double-blind, Placebo-controlled Clinical Trial Unknown status NCT02276235 Phase 4
28 Prospective, Randomized, Double - Blind, Placebo Controlled Trial of Dietary Modification in Conjunction With Probiotic Therapy on Clinical and Endocrinological Parameters as Well as Body Composition in Women With Polycystic Ovary Syndrome Unknown status NCT03325023 Phase 4
29 Comparing the Efficacy of Two Frequently Used Doses of Enoxaparin for VTE Prophylaxis After Bariatric Surgery Unknown status NCT01970202 Phase 4 40mg Enoxaparin;60mg Enoxaparin
30 International, Multi Centre, Open, Prospective, Randomized Study: Banded Versus Conventional Laparoscopic Roux-en-Y (GABY) Unknown status NCT01015469 Phase 4
31 Influence of Erythromycin on ad Libitum Food Intake and the Evaluation of Motilin in Food Timing in Healthy Volunteers and Patients Unknown status NCT03024879 Phase 4 Erythromycin;Saline
32 Vitamin Deficiencies and Suppletion in Morbid Obesity Unknown status NCT02270749 Phase 4 Hydroxocobalamin;FitForMe vitamin B12
33 What is the Effects of Incretin on the Blood Pressure and Lipid in Overweight or Obese Diabetes Patients With Masked Hypertension: Liraglutide Plus Mitiglinide Comparing Metformin Plus Mitiglinide or Mitiglinide Alone(BLOOD STUDY) Unknown status NCT02503943 Phase 4 "Liraglutide" and "Mitiglinide";"Metformin" and "Mitiglinide";"Mitiglinide"
34 Weight Reduction Alone May Not be Sufficient to Maintain Disease Remission in Obese Patients With Psoriasis: a Randomized, Investigator-blinded Study Unknown status NCT01439425 Phase 4
35 Aromatase Inhibitors and Weight Loss in Severely Obese Hypogonadal Male Veterans (Pilot) Unknown status NCT02959853 Phase 4 Anastrazole
36 Prospective Randomized Study of Effects of Laparoscopic Roux-en-Y Gastric Bypass Versus Laparoscopic Sleeve Gastrectomy Unknown status NCT00667706 Phase 4
37 Gut Hormones as Mediators of Different Weight Loss Responses After Roux-en-Y Gastric Bypass Unknown status NCT02374632 Phase 4
38 The Effect of Exenatide on Brown Adipose Tissue Activity and Energy Expenditure in Healthy Young Men Unknown status NCT03002675 Phase 4 Bydureon
39 Prospective Randomized Trials of Gastric Bypass Surgery in Patients With Type II Diabetes Mellitus Unknown status NCT00540462 Phase 4
40 What is the Effects of Prokinetic Drug on the Blood Glucose in Type 2 Diabetes Patients: Mosapride Comparing Placebo Unknown status NCT02606617 Phase 4 Mosapride;Placebo
41 Efficacy of Vitamin D Supplementation in Obese Children Unknown status NCT02956408 Phase 4
42 The Effect of Mirabegron on Brown Adipose Tissue in Healthy Young White Caucasian and South Asian Men Unknown status NCT03012113 Phase 4 Mirabegron;Placebo Oral Capsule
43 Sildenafil Activates Browning of White Adipose and Improves Insulin Sensitivity in Human Adults Unknown status NCT02524184 Phase 4 sildenafil;placebo
44 BARI-OPTIMISE: a Double-blinded, Randomised, Placebo-controlled Trial of Liraglutide 3.0 mg in Patients With Poor Weight-loss and a Suboptimal Glucagon-like Peptide-1 Response Following Bariatric Surgery Unknown status NCT03341429 Phase 4 Liraglutide Pen Injector [Saxenda];Placebo
45 The Research About the Influence of Medical Interventions in the Period of Insulin Resistance on Prevalence of Abnormal Glucose Tolerance Unknown status NCT02502344 Phase 4 Metformin
46 Influence of the Aromatase Inhibitor Letrozole on Heart and Liver Function in Obese Men Unknown status NCT02097680 Phase 4 Letrozole;Placebo
47 Changes in Central Aortic Pressure, Endothelial Function and Biomarkers in African Americans With Cardiometabolic Syndrome: Comparison of Amlodipine/Olmesartan Versus Hydrochlorothiazide/Losartan Unknown status NCT01271374 Phase 4 amlodipine and olmesartan;losartan and HCTZ
48 Study of the Concentrations of Long Acting Morphine After Oral Absorption in Subjects Who Underwent Gastric Bypass (OBEMO 2) Unknown status NCT02641301 Phase 4 Sustained release morphine sulfate, 30 mg
49 Effect of aSpirin Versus CilOstazol for Inhibition of Antiplatelet aggRegaTion in Type 2 DM Patients Unknown status NCT02933788 Phase 4 Cilostazol;Acetylsalicylic acid
50 Determining the Minimal Effective Volume (MEAV95) for Interscalene Brachial Plexus Block for Surgical Anesthesia Unknown status NCT01703130 Phase 4

Search NIH Clinical Center for Body Mass Index Quantitative Trait Locus 4

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Benzphetamine
Benzphetamine hydrochloride
Dexfenfluramine
Dexfenfluramine Hydrochloride
Diethylpropion
Diethylpropion Hydrochloride
Fenfluramine
Fenfluramine Hydrochloride
lorcaserin
lorcaserin hydrochloride
Mazindol
Methamphetamine
orlistat
phendimetrazine
PHENDIMETRAZINE HYDROCHLORIDE
phendimetrazine tartrate
Phenmetrazine
Phenmetrazine Hydrochloride
Phentermine
Phentermine Hydrochloride
PHENTERMINE RESIN
Phenylpropanolamine
Phenylpropanolamine Hydrochloride
sibutramine
SIBUTRAMINE HYDROCHLORIDE

Genetic Tests for Body Mass Index Quantitative Trait Locus 4

Genetic tests related to Body Mass Index Quantitative Trait Locus 4:

# Genetic test Affiliating Genes
1 Body Mass Index Quantitative Trait Locus 4 29 UCP2

Anatomical Context for Body Mass Index Quantitative Trait Locus 4

MalaCards organs/tissues related to Body Mass Index Quantitative Trait Locus 4:

40
Liver, Heart, Breast, Brain, Testes, Kidney, Endothelial

Publications for Body Mass Index Quantitative Trait Locus 4

Articles related to Body Mass Index Quantitative Trait Locus 4:

(show top 50) (show all 30003)
# Title Authors PMID Year
1
A common polymorphism in the promoter of UCP2 is associated with decreased risk of obesity in middle-aged humans. 56 6
11381268 2001
2
The common -866G/A polymorphism in the promoter region of the UCP-2 gene is associated with reduced risk of type 2 diabetes in Caucasians from Italy. 6
15562023 2005
3
Association between uncoupling protein polymorphisms (UCP2-UCP3) and energy metabolism/obesity in Pima indians. 56
9700198 1998
4
Leptin, obesity, and response to ketamine. 61
31672525 2020
5
Association between community greenness and obesity in urban-dwelling Chinese adults. 61
31726339 2020
6
Circannual growth in Wisconsin children and adolescents: Identifying optimal periods of obesity prevention. 61
31595686 2020
7
Relationship Between Obesity and Balance in the Community-Dwelling Elderly Population: A Cross-Sectional Analysis. 61
31464747 2020
8
Role of skeletal muscle autophagy in high-fat-diet-induced obesity and exercise. 61
31529063 2020
9
Complex interaction of obesity, intentional weight loss and heart failure: a systematic review and meta-analysis. 61
31530572 2020
10
Differences in Health Education Competencies Among Obesity Prevention and Nutrition Education Professionals. 61
30071764 2020
11
Late Adiposity Rebound and the Probability of Developing and Reversing Childhood Obesity. 61
31676030 2020
12
Tetrahydrocannabinolic acid A (THCA-A) reduces adiposity and prevents metabolic disease caused by diet-induced obesity. 61
31706843 2020
13
Role of Zinc in Zinc-α2-Glycoprotein Metabolism in Obesity: a Review of Literature. 61
30929134 2020
14
Diverging trends in obesity, diabetes, and raised blood pressure in the Americas. 61
31839131 2020
15
Obesity Prevention Worksite Wellness Interventions for Health Care Workers: A Narrative Review. 61
31818235 2020
16
Mechanism of SEMA3G knockdown-mediated attenuation of high-fat diet-induced obesity. 61
31648186 2020
17
Metaanalysis on obesity and risk of inflammatory bowel disease: Reanalysis is needed. 61
31692191 2020
18
Trends in Tract-Level Prevalence of Obesity in Philadelphia by Race-Ethnicity, Space, and Time. 61
31688128 2020
19
Toward isolating reward changes in diet-induced obesity: A demand analysis. 61
31678579 2020
20
Early mother-child dyadic pathways to childhood obesity risk: A conceptual model. 61
31533059 2020
21
Obesity and 1-Year Mortality in Adults After Sepsis: A Systematic Review. 61
31533460 2020
22
Obesity Prevention Worksite Wellness Interventions for Health Care Workers: A Narrative Review. 61
31451058 2020
23
Cultural Influences on Childhood Obesity in Ethnic Minorities: A Qualitative Systematic Review. 61
31423926 2020
24
The association of angiopoietin-like peptide 4 levels with obesity and hepatosteatosis in adolescents. 61
31419758 2020
25
Transgenic mice expressing human IL-32 develop adipokine profiles resembling those of obesity-induced metabolic changes. 61
31398626 2020
26
Monogenic leptin deficiency in early childhood obesity. 61
31483094 2020
27
Massive Cardiomegaly (>1000 g Heart) and Obesity. 61
31847959 2020
28
The Impact of Obesity in Heart Failure. 61
31735317 2020
29
Novel Intragenic PAX6 Deletion in a Pedigree with Aniridia, Morbid Obesity, and Diabetes. 61
31361967 2020
30
Resveratrol alleviates obesity-associated podocyte injury in ovariectomized obese rats. 61
31853281 2020
31
Obesity: a neuroimmunometabolic perspective. 61
31776456 2020
32
Gestational oxidative stress protects against adult obesity and insulin resistance. 61
31550664 2020
33
Association of maternal obesity and neonatal hypoxic ischemic encephalopathy. 61
31748656 2020
34
Re: Effects of Bariatric Surgery in Male Obesity-Associated Hypogonadism. 61
31625794 2020
35
Skeletal muscle adiponectin induction in obesity and exercise. 61
31706980 2020
36
SGK1 activation exacerbates diet-induced obesity, metabolic syndrome and hypertension. 61
31600722 2020
37
Green spaces, excess weight and obesity in Spain. 61
31679857 2020
38
Challenges in obesity and primary aldosteronism: Diagnosis and treatment. 61
31542169 2020
39
Telmisartan prevents development of obesity and normalizes hypothalamic lipid droplets. 61
31585441 2020
40
A brief overview of the challenges of acupuncture trials in obesity. 61
31779996 2019
41
Effects of Spirulina supplementation on obesity: A systematic review and meta-analysis of randomized clinical trials. 61
31780031 2019
42
Annual Report on Children's Healthcare: Healthcare Access and Utilization by Obesity Status in the United States. 61
31843708 2019
43
Leptin, adiponectin and their ratio as markers of insulin resistance and cardiometabolic risk in childhood obesity. 61
31845423 2019
44
Women, obesity, and the incidence of heart failure: An uncertainty that has begun to be solved. 61
31801047 2019
45
NADPH oxidase 4 mediates the protective effects of physical activity against obesity-induced vascular dysfunction. 61
31800011 2019
46
Health service utilization and direct healthcare costs associated with obesity in older adult population in Ghana. 61
31800054 2019
47
Kruppel-like factor 4 improves obesity-related nephropathy through increasing mitochondrial biogenesis and activities. 61
31800161 2019
48
Aboriginal childhood overweight and obesity: the need for Aboriginal designed and led initiatives. 61
31800643 2019
49
Impact of Gait Speed on the Obesity Paradox in Older Patients With Cardiovascular Disease. 61
31356768 2019
50
Anti-obesity effects of enzyme-treated celery extract in mice fed with high-fat diet. 61
31788817 2019

Variations for Body Mass Index Quantitative Trait Locus 4

ClinVar genetic disease variations for Body Mass Index Quantitative Trait Locus 4:

6 ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 UCP2 NM_003355.2(UCP2):c.-1245G>ASNV risk factor 7865 rs659366 11:73694754-73694754 11:73983709-73983709
2 UCP2 NM_003355.2(UCP2):c.79G>A (p.Ala27Thr)SNV Uncertain significance 437204 rs201315561 11:73689345-73689345 11:73978300-73978300

Expression for Body Mass Index Quantitative Trait Locus 4

Search GEO for disease gene expression data for Body Mass Index Quantitative Trait Locus 4.

Pathways for Body Mass Index Quantitative Trait Locus 4

GO Terms for Body Mass Index Quantitative Trait Locus 4

Sources for Body Mass Index Quantitative Trait Locus 4

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....